| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 219.06 | 5.5% | 32.4% |
| Total Income | 219.06 | 5.5% | 32.4% |
| Expenditure | 277.02 | 28.2% | 80.7% |
| PBT | -57.65 | 868.9% | 445.8% |
| Net Profit | -58.37 | 2448.9% | 359.4% |
| OPM | -26.46% | 22.45pp | 33.80pp |
| NPM | -26.65% | 25.54pp | 40.24pp |
| EPS | -1.01 | 2425.0% | 352.5% |
Supernus Pharmaceuticals Announces Q2 2026 Earnings Release Date
23 Jul 2026 · 23 Jul, 2:41 am
Management Comments
J
Jack Khattar
Will host a conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss these results.
T
Tim Dec
Will host a conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss these results.
Informational and educational content only. Not investment advice.